Metabolic syndrome: Relevance to psychiatry

Pakistan Journal of Medical Sciences

Volumn 24, Issue 1, 2008, Pages 181-186

  Javed, Afzal ^a,c   Afzal, Maryam ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Foundation Year   (United Kingdom)

^c Medical Centre   (United Kingdom)

Author keywords

Antipsychotic drugs; Lifestyle management; Mental disorders; Metabolic syndrome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MENTAL DISEASE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 40549085667     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol Suppl 2005;19(6):84-93.
2. Davidson MB. Metabolic syndrome / insulin resistance syndrome / pre-diabetes: new section in diabetic care. Diabetes Care 2003;26:3179.
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetic Care 2004;27:2444-9.
4. National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third report of NCEP. JAMA 2001;2486-97.
5. Bloomgarden ZT. Definition of insulin resistance syndrome: the 1st World Congress on the Insulin resistance syndrome. Diabetes Care 2004;27:824-30.
6. American Diabetic Association: American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and diabetes. Diabetes Care 2004; 27: 596-601
7. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetic Care 2003;26:575-81.
8. Lakha HM, Leaksonen DE, Lakka TA, Niskanen, LK, Kumppusalo E, Tuomilehto J, et al. The metabolic syndrome and total cardiovascular disease mortality in middle aged man. JAMA 2002;288:2709-16.
9. Katzmaryzyk PT. The Canadian obesity epidemic, 1985 - 1998. CMAJ 2002; 166: 1039-40
10. Kanauchi M, Kanauchi K, Hashimoto T, Saito Y. Metabolic syndrome and new category "pre-hypertension" in a Japanese population. Curr Med Res Opin 2004;20:1365-70.
11. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal weight Americans: New definition of the metabolically obese, normal-weight individual. Diabetes Care 2004;27:2222-8.
12. Mukhopadhyay B, Sattar N, Fisher M. Diabetes and cardiac disease in South Asians. Br J Diabetes Vas Dis 2005;5:253-9.
13. Citrome L, Blonde l, Damatarca C. Metabolic issues in patients with severe mental illness. Southern Med J 2005;98:714-20.
14. Phelan M, Stradins L, Morrisons S. Physical health of people with severe mental illness. BMJ 2001;322:443-4.
15. Ohlsen R, Peacock G, Smith S, Pilowsky I. Assessing physical health in an urban population of people with serious mental illness. Schizophr Bull 2005;21:S567.
16. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry 2005;186:455-6.
17. Kessing LV, Nilsson FM, Siersma V, Anderson PK. Increased risk of developing diabetes in depressive and bipolar disorders. J Psych Res 2004;38:395-402.
18. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of metabolic syndrome in patients with schizoaffective disorders- bipolar subtype. Bipoalr Dosrd 2004;6:314-18.
19. Ryan MCM, Thakore, JH. Physical cosequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71:239-57.
20. McCreadie RG. Scotish Lifestyle Group Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-9.
21. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-45.
22. Brown S, Inskip H, Barraaclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-17.
23. Kohen D. Diabetes Mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;184:S64-6.
24. Expert consensus meeting "Schizophrenia and diabetes 2003, Dublin, 3-4 October: Consensus summary. Br J Psychiatry Suppl 2004;47:S112-14.
25. Maudsley H. The pathology of mind (3rd edition) 1879. Macmillan, London.
26. Raphael T. Blood sugar studies in demential praecox and manic depressive insanity. Arch Neur Psychiatry 1921;5:687-709.
27. Susce MT Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a crosssectional survey. J Clin Psychiatry 2005;66:167-73.
28. Canadian Diabetic Association Clinical Practice Guidelines Expert Committee. CDA Clinical Practice Guidelines for the prevention and management of Diabetes: screening and prevention. Canadian J Diabetes Suppl 2003;27:S10-S33.
29. Austin MA, Hokansen JE, Edwards Kl. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
30. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemic of obesity and diabetes in the United States. JAMA 2001;286:1195-1200.
31. Durrington P. Dyslipidaemia. Lancet 2003;362:717-31.
32. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive, JM, et al. The National Institute of Mental Health Clinical antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trials design a protocol development. Schizophrenia Bulletin 2003;29:15-31.
33. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, et al. Hyperlipidaemia in persons using antipsychotic medication: A general population based birth cohort study. J Clin Psychiatry 2004;65:547-50.
34. Davis JM, Chen N, Glick ID. A Meta analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
35. O'Brien P, Oyebode F. Psychotropic medication and the heart. Advances in Psychiatric Treatment 2003;9:414-23.
36. Lindenmayer JP. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
37. Zhang ZJ, Yao ZL, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. MRI study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62.
38. Sernyak M, Leslie D, Alarcan R, Losonczy M, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
39. Dinan TG (ed). Schizophrenia and diabetes 2003: an expert meeting. Br J Psychiatry Suppl 2004;47:S53-S54.
40. Citrome LL. Antipsychotic medication and diabetes mellitus. J Clin Psychiatry 2005;66:395-7.
41. Tighe S, Dinan T. An overview of the central control of weight regulation and the effect of antipsychotic medication. J Psychopharm Suppl 2005;19(6):36-46.
42. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-6.
43. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
44. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizphr Res 2004;71:195-212.
45. Klett C, Caffey E. Weight changes in relation to the characteristics of patients on chlorpromazine. J Neuropsychiatry 1960;2:102-8.
46. Wirshing DA, Wirshing WC, Kysar l, Bersiford MA, Goldstein D, Pashag J. Noval antipsychotics; comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
47. Taylor DM, McAskill R. Atypical antipsychotics & weight gain - A systematic review. Acta Psychiatr Scand 2000;101:416-32.
48. Gough SC, O'Donovan MC. Clustring of metabolic comorbidity in schizophrenia: A genetic contribution? J Psychopharm Suppl 2005;19:6:47-55.
49. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, et al. Risk of weight gain associated with antipsychotic treatment: Results from the Canadian National Outcome Measurement Study in Schizophrenia. Can J Psychiatry 2003;48(10):689-94.
50. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry Suppl 2004;47:S87-S93.
51. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy SK. Clozapinr, Rieperidone, Olanzapine and conventional antipsychotic drug effects on glucose, lipids and leptons in schizophrenic patients. Int J Neuropsychopharmacol 2005;8:183-94.
52. Shafique M, Khan IA, Akhtar MH, Hussain I. Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers. J Pak Med Assoc 1988;38:259-61.
53. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry Suppl 2001;27:27-34.
54. Meyer JM, Kore CE. The effects of antipsychotics therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17.
55. Paton C. Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305.
56. Lambert BL, Chang KY, Tafasse E, Carson W. Association between antipsychotic treatment and hyperlipdaemia among Califonia Medicaid patients with schizophrenia. J Clin Pychopharmacology 2005;25:12-8.
57. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35:196-202.
58. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150(6):1115-21.
59. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry 2006;19(4):432-7.
60. Dembling BP, Chen DT, Vachon L. Life expectancy and causes of death in a population treated for serious mental illness. Psychiatr Serv 1999;50(8):1036-42.
61. Lawrence D, Jablensky AV, Holman CDJ, Pinder TJ. Mortality in Western Australian psychiatric patients. Soc Psychiatry Psychiatr Epidemiol 2000;35(8):341-7.
62. Kurihara T, Kato M, Kashima H, Takebayashi T, Reverger R, Tirta IGR. Excess mortality of schizophrenia in the developing country of Bali. Schizophr Res. 2006;83(1):103-5.
63. Saha S, Chant D, McGrath J. A Systematic Review of Mortality in Schizophrenia. Is the Differential Mortality Gap Worsening Over Time? Arch Gen Psychiatry 2007;64(10):1123-31.
64. Druss BG, Bradford WD, Rosenheck RA. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-72.
65. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-49.
66. Coghlan R, Lawrence D, Jablensky A. Duty to Care: Physical Illness in People with Mental Illness. Perth: The University of Western Australia; 2001.
67. Byng R. Physical care for patients with mental illness. Practitioner 2004;248:440-5.
68. Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry 2006;163(7):1132-4.
69. Brown S, Birtwistle J, Roe l, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
70. National Institute for Clinical Excellence (NICE) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Techanology Appraisal Guidance No 43. 2002; London Available at:http;//www.nice.org.uk
71. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association, steering committee on practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry Sppl 2004;161:1-56.
72. Lloyd C, Sullivan D. NEW solutions: an Australian health promotion programme for people with mental illness. Int J Therapy Rehab 2003;10(5):204-10.
73. Ganguli R, Brar JS. Prevention of weight gain by behavioral interventions in patients starting on noval antipsychotics. Schizophr Bull 2005;21:S561. 187-188